Were the Xeris Biopharma (XERS) insider share sales pre-planned?

Yes, the sale was executed under a Rule 10b5-1 trading plan. The footnotes state the plan was adopted on September 12, 2025, meaning the 16,000-share sale at a weighted average price of $6.0942 was scheduled in advance under SEC rules.

Xeris Biopharma (XERS) director trades stock and receives new equity awards

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Xeris Biopharma Holdings director Barbara-Jean Anne Bormann-Kennedy reported a mix of equity awards and a stock sale. She received 24,193 shares of common stock as a restricted stock unit grant under the company’s 2018 Stock Option and Incentive Plan, at no cash cost.

She also received stock options for 32,996 shares of common stock at an exercise price of $6.15 per share, expiring on June 4, 2036. Both the restricted stock and the options vest in full on the earlier of June 4, 2026 or the company’s next annual meeting of stockholders, subject to continued service.

On the same date, she sold 16,000 shares of common stock in an open-market transaction at a weighted average price of $6.0942 per share, executed pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025. After these transactions, she holds 126,500 common shares directly.

Insights

Routine director equity awards combined with a pre-planned partial share sale.

The transactions show a standard director compensation structure at Xeris Biopharma Holdings, with 24,193 restricted shares and options for 32,996 shares at $6.15 per share, both vesting by the earlier of the next annual meeting or June 4, 2026.

The sale of 16,000 shares at a weighted average of $6.0942 occurred under a pre-arranged Rule 10b5-1 trading plan, which suggests the timing was scheduled in advance rather than opportunistic. Following the sale, the director still holds 126,500 shares, indicating she retains a substantial equity position.

There are no derivative exercises in this filing, only new option grants expiring in 2036. Overall, this appears to be routine governance and compensation activity with a modest, pre-planned liquidity event, rather than a significant change in insider exposure.

Insider Trade Summary 10b5-1

Net Seller: 16,000 shares ($97,507)

Net Sell 3 txns

Insider BORMANN-KENNEDY BARBARA-JEAN ANNE

Role null

Sold 16,000 shs ($98K)

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,996	$6.15	$203K
Sale	Common Stock	16,000	$6.0942	$98K
Grant/Award	Common Stock	24,193	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,996 shares (Direct, null); Common Stock — 126,500 shares (Direct, null)

Footnotes (1)

The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Key Figures

Restricted stock grant: 24,193 shares Stock sale: 16,000 shares Sale price: $6.0942 per share +4 more

7 metrics

Restricted stock grant 24,193 shares Common stock awarded as RSUs on June 4, 2026 vesting schedule

Stock sale 16,000 shares Open-market sale at weighted average $6.0942 per share

Sale price $6.0942 per share Weighted average price range $5.970 to $6.170

Option grant size 32,996 shares Stock options granted with underlying common shares

Option exercise price $6.15 per share Exercise price for stock options expiring June 4, 2036

Post-transaction holdings 126,500 shares Common shares held directly after transactions

Option expiration June 4, 2036 Expiration date of newly granted stock options

Key Terms

Rule 10b5-1 trading plan, restricted stock unit, weighted average price, stock options, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock unit financial

"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

stock options financial

"These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2018 Stock Option and Incentive Plan financial

"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 06:18 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BORMANN-KENNEDY BARBARA-JEAN ANNE

(Last)

(First)

(Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO

ILLINOIS

60607

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/04/2026		S⁽¹⁾		16,000	D	$6.0942⁽²⁾	126,500	D
Common Stock	06/04/2026		A		24,193⁽³⁾	A	$0	150,693	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.15	06/04/2026		A		32,996		⁽⁴⁾	06/04/2036	Common Stock	32,996	$6.15	32,996	D

Explanation of Responses:

1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.970 to $6.170, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

4. These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders, subject to continued service through such vesting date.

Remarks:

	/s/ Beth Hecht, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Xeris Biopharma (XERS) director Bormann-Kennedy report?

She reported receiving restricted stock and options and selling shares. The filing shows a grant of 24,193 common shares, stock options for 32,996 shares at $6.15, and an open-market sale of 16,000 shares at a weighted average price of $6.0942.

How many Xeris Biopharma (XERS) shares does the director hold after these transactions?

After the reported transactions, the director directly holds 126,500 common shares. This figure reflects the net position following the grant of 24,193 restricted shares and the open-market sale of 16,000 shares disclosed in the Form 4 filing.

What are the terms of the new Xeris Biopharma (XERS) stock options granted?

The director received options for 32,996 shares at an exercise price of $6.15. These options vest in full on the earlier of June 4, 2026, or the company’s next annual shareholder meeting and expire on June 4, 2036, subject to continued service.

When do the Xeris Biopharma (XERS) restricted stock units vest for the director?

The 24,193 restricted shares vest in full on the earlier of June 4, 2026, or the next annual meeting. Vesting depends on the director’s continued service through that date, aligning equity compensation with ongoing board participation and company oversight.